Invitrogen Expands High-Throughput Assays With Molecular Probes Purchase
This article was originally published in The Gray Sheet
Executive Summary
Invitrogen will enhance its high-throughput, drug discovery screening assays with Molecular Probes, Inc.'s fluorescent molecular labeling detection systems under a $325 mil. proposed acquisition
You may also be interested in...
Fisher Casts For Proteomics Consumables; Perbio Deal Offers Device Angle
Fisher Scientific will explore the viability of Perbio Science AB's medical device unit within a planned merger of the two companies, announced June 26
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.